Cargando…

Four distinct immune microenvironment subtypes in gastric adenocarcinoma with special reference to microsatellite instability

INTRODUCTION: Programmed death-ligand 1 (PD-L1) can be overexpressed in tumours other than Epstein-Barr virus (EBV)-positive (EBV(+)) or microsatellite instability-high (MSI-H) gastric cancer (GC) subtypes. We aimed to determine the tumour immune microenvironment (TME) classification of GC to better...

Descripción completa

Detalles Bibliográficos
Autores principales: Cho, Junhun, Chang, Young Hwan, Heo, You Jeong, Kim, Seungtae, Kim, Nayoung KD, Park, Joon Oh, Kang, Won Ki, Lee, Jeeyun, Kim, Kyoung-Mee
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5890063/
https://www.ncbi.nlm.nih.gov/pubmed/29636988
http://dx.doi.org/10.1136/esmoopen-2018-000326
_version_ 1783312793538134016
author Cho, Junhun
Chang, Young Hwan
Heo, You Jeong
Kim, Seungtae
Kim, Nayoung KD
Park, Joon Oh
Kang, Won Ki
Lee, Jeeyun
Kim, Kyoung-Mee
author_facet Cho, Junhun
Chang, Young Hwan
Heo, You Jeong
Kim, Seungtae
Kim, Nayoung KD
Park, Joon Oh
Kang, Won Ki
Lee, Jeeyun
Kim, Kyoung-Mee
author_sort Cho, Junhun
collection PubMed
description INTRODUCTION: Programmed death-ligand 1 (PD-L1) can be overexpressed in tumours other than Epstein-Barr virus (EBV)-positive (EBV(+)) or microsatellite instability-high (MSI-H) gastric cancer (GC) subtypes. We aimed to determine the tumour immune microenvironment (TME) classification of GC to better understand tumour–immune interactions and help patient selection for future immunotherapy with special reference to MSI-H. METHODS: Immunohistochemistry (IHC) for PD-L1 and CD8(+) T cells in three distinct subtypes of GC (43 EBV(+), 79 MSI-H and 125 EBV(−)/MSS) were performed and analysed. In 66 MSI-H GC, mutation counts were compared with PD-L1 expression and survival of the patients. RESULTS: GC TME divided by PD-L1 IHC and tumour-infiltrating lymphocytes (TIL) measured by intratumoural CD8 density showed: (1) about 40% of GC are type I (PD-L1(+)/TIL(+)) consisting ~70% of MSI-H or EBV(+) GC, and ~15% of EBV(−)/microsatellite stable (MSS) GC patients show the best survival in both disease-free (HR 2.044) and overall survival (HR 1.993); this type would respond to a checkpoint blockade therapy; (2) almost 30% of GC are type II (PD-L1(−)/TIL(−)) with the worst survival; (3) approximately 10% of GC are type III (PD-L1(+)/TIL(−)); and (4) up to 20% are type IV (PD-L1(−)/TIL(+)) and, unexpectedly, ~25% of EBV(+) or MSI-H GC are within this subtype. In MSI-H GC, frequent frameshift mutations were observed in ARID1A, RNF43, NF1, MSH6, BRD3, NCOA3, BCORL1, TNKS2 and NPM1 and the numbers of frameshift mutation correlated significantly with PD-L1 expression (P<0.05). DISCUSSION: GC can be classified into four TME types based on PD-L1 and TIL, and numbers of frameshift mutation correlate well with PD-L1 expression in MSI-H GC.
format Online
Article
Text
id pubmed-5890063
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-58900632018-04-10 Four distinct immune microenvironment subtypes in gastric adenocarcinoma with special reference to microsatellite instability Cho, Junhun Chang, Young Hwan Heo, You Jeong Kim, Seungtae Kim, Nayoung KD Park, Joon Oh Kang, Won Ki Lee, Jeeyun Kim, Kyoung-Mee ESMO Open Original Research INTRODUCTION: Programmed death-ligand 1 (PD-L1) can be overexpressed in tumours other than Epstein-Barr virus (EBV)-positive (EBV(+)) or microsatellite instability-high (MSI-H) gastric cancer (GC) subtypes. We aimed to determine the tumour immune microenvironment (TME) classification of GC to better understand tumour–immune interactions and help patient selection for future immunotherapy with special reference to MSI-H. METHODS: Immunohistochemistry (IHC) for PD-L1 and CD8(+) T cells in three distinct subtypes of GC (43 EBV(+), 79 MSI-H and 125 EBV(−)/MSS) were performed and analysed. In 66 MSI-H GC, mutation counts were compared with PD-L1 expression and survival of the patients. RESULTS: GC TME divided by PD-L1 IHC and tumour-infiltrating lymphocytes (TIL) measured by intratumoural CD8 density showed: (1) about 40% of GC are type I (PD-L1(+)/TIL(+)) consisting ~70% of MSI-H or EBV(+) GC, and ~15% of EBV(−)/microsatellite stable (MSS) GC patients show the best survival in both disease-free (HR 2.044) and overall survival (HR 1.993); this type would respond to a checkpoint blockade therapy; (2) almost 30% of GC are type II (PD-L1(−)/TIL(−)) with the worst survival; (3) approximately 10% of GC are type III (PD-L1(+)/TIL(−)); and (4) up to 20% are type IV (PD-L1(−)/TIL(+)) and, unexpectedly, ~25% of EBV(+) or MSI-H GC are within this subtype. In MSI-H GC, frequent frameshift mutations were observed in ARID1A, RNF43, NF1, MSH6, BRD3, NCOA3, BCORL1, TNKS2 and NPM1 and the numbers of frameshift mutation correlated significantly with PD-L1 expression (P<0.05). DISCUSSION: GC can be classified into four TME types based on PD-L1 and TIL, and numbers of frameshift mutation correlate well with PD-L1 expression in MSI-H GC. BMJ Publishing Group 2018-03-15 /pmc/articles/PMC5890063/ /pubmed/29636988 http://dx.doi.org/10.1136/esmoopen-2018-000326 Text en © European Society for Medical Oncology (unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted. This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
spellingShingle Original Research
Cho, Junhun
Chang, Young Hwan
Heo, You Jeong
Kim, Seungtae
Kim, Nayoung KD
Park, Joon Oh
Kang, Won Ki
Lee, Jeeyun
Kim, Kyoung-Mee
Four distinct immune microenvironment subtypes in gastric adenocarcinoma with special reference to microsatellite instability
title Four distinct immune microenvironment subtypes in gastric adenocarcinoma with special reference to microsatellite instability
title_full Four distinct immune microenvironment subtypes in gastric adenocarcinoma with special reference to microsatellite instability
title_fullStr Four distinct immune microenvironment subtypes in gastric adenocarcinoma with special reference to microsatellite instability
title_full_unstemmed Four distinct immune microenvironment subtypes in gastric adenocarcinoma with special reference to microsatellite instability
title_short Four distinct immune microenvironment subtypes in gastric adenocarcinoma with special reference to microsatellite instability
title_sort four distinct immune microenvironment subtypes in gastric adenocarcinoma with special reference to microsatellite instability
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5890063/
https://www.ncbi.nlm.nih.gov/pubmed/29636988
http://dx.doi.org/10.1136/esmoopen-2018-000326
work_keys_str_mv AT chojunhun fourdistinctimmunemicroenvironmentsubtypesingastricadenocarcinomawithspecialreferencetomicrosatelliteinstability
AT changyounghwan fourdistinctimmunemicroenvironmentsubtypesingastricadenocarcinomawithspecialreferencetomicrosatelliteinstability
AT heoyoujeong fourdistinctimmunemicroenvironmentsubtypesingastricadenocarcinomawithspecialreferencetomicrosatelliteinstability
AT kimseungtae fourdistinctimmunemicroenvironmentsubtypesingastricadenocarcinomawithspecialreferencetomicrosatelliteinstability
AT kimnayoungkd fourdistinctimmunemicroenvironmentsubtypesingastricadenocarcinomawithspecialreferencetomicrosatelliteinstability
AT parkjoonoh fourdistinctimmunemicroenvironmentsubtypesingastricadenocarcinomawithspecialreferencetomicrosatelliteinstability
AT kangwonki fourdistinctimmunemicroenvironmentsubtypesingastricadenocarcinomawithspecialreferencetomicrosatelliteinstability
AT leejeeyun fourdistinctimmunemicroenvironmentsubtypesingastricadenocarcinomawithspecialreferencetomicrosatelliteinstability
AT kimkyoungmee fourdistinctimmunemicroenvironmentsubtypesingastricadenocarcinomawithspecialreferencetomicrosatelliteinstability